Context Therapeutics Inc.

Healthcare · Biotechnology · United States

Last price 0.1891 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 17.37M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors. The company’s product candidate includes CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. It has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Penn...